BAVA Bavarian Nordic A/S

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

Bavarian Nordic stock has delivered a solid 36.1% return over the past three years, while a fresh intrinsic value estimate using a Discounted Cash Flow (DCF) approach indicates the shares trade at a sizeable discount to that model. At the same time, market based multiples look roughly in line with peers, which leaves investors weighing a high value score against a more neutral read from traditional ratios. Over the past three years the share price is up 36.1%, which signals that investors...

Bavarian Nordic AS (BVNKF) raises FY2026 revenue and EBITDA guidance on robust Travel Health and Public Preparedness performance, while navigating Chikungunya headwinds and advancing its pipeline.